We can’t show the full text here under this license.
Abstract
Lipid nanoparticles (LNPs) are recognized for their role in delivering RNA therapeutics, but current formulations predominantly target the liver.
- Most clinically approved LNP formulations exhibit strong liver tropism, which limits their effectiveness in targeting other tissues.
- Engineering efforts include surface modifications with targeting ligands that may enhance uptake by specific immune cells, such as macrophages and T lymphocytes.
- Advancements in lipid design could improve the delivery of RNA by aiding in the escape of the therapeutic from endosomes.
- Functionalized LNPs are being explored for applications in treating inflammatory disorders like autoimmune diseases and neuroinflammation.
- Investigations are ongoing into the use of functionalized LNPs for the in vivo engineering of immune cells.
Simplified